«Launch of a European clinical trial against COVID-19». INSERM. 22 de marzo de 2020. Consultado el 5 de abril de 2020. «The great strength of this trial is its “adaptive” nature. This means that ineffective experimental treatments can very quickly be dropped and replaced by other molecules that emerge from research efforts. We will therefore be able to make changes in real time, in line with the most recent scientific data, in order to find the best treatment for our patients».
